Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2025-02-12 00:00:00 ET · period of report 2025-02-10 · accession 0000875320-25-000033 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-12 | 2025-02-10 | VRTX | Ambrose Kristen | SVP, CAO | F - Tax | $467.98 | -591 | 11.3K | -5% | -$276.6K | |
| 2025-02-12 | 2025-02-11 | VRTX | Ambrose Kristen | SVP, CAO | S - Sale | $459.83 | -1,376 | 9,953 | -12% | -$632.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-10 | F | D | 591 | $467.98 | 11,329 | D | — | — | |
| 2 | Common | Common Stock | 2025-02-11 | S | D | 1,376 | $459.83 | 9,953 | D | — | — |